Healthcare Realty (HR) Q2 2026 earnings review
Transformation Validated: Capital Recycling Accelerates
Healthcare Realty's Q2 2026 results confirm that its 'Healthcare Realty 2.0' strategic pivot is firmly intact. Following a massive $1.2B deleveraging disposition program in 2025, the company has seamlessly transitioned to offense. Same-store cash NOI grew a robust 5.1% YoY, proving the company can break the legacy 2-3% growth stereotype of the medical office building (MOB) sector. More importantly, management executed highly accretive capital recycling: selling $83M of lower-growth assets at sub-5% cap rates to fund $200M in joint venture acquisitions at a ~7.5% cash yield. This aggressive arbitrage, combined with a well-covered 76% FAD payout ratio and an upward guidance revision, demonstrates strong operational command.
🐂 Bull Case
Selling assets at a sub-5% cap rate and reinvesting into JV acquisitions at a 7.5% yield creates massive, immediate earnings accretion without stressing the balance sheet.
Tenant retention sits at a lofty 88.5% and cash leasing spreads are positive at 4.8%, giving the company leverage to drive organic same-store growth well above historical industry averages.
🐻 Bear Case
Same-store NOI growth decelerated sequentially from 6.9% in Q1 to 5.1% in Q2. As comparisons get tougher, maintaining this elevated growth rate will be challenging.
Same-store occupancy is healthy at 92.7%, but total portfolio occupancy lags at 90.7%. Management must execute on the 'lease-up' bucket to fully realize their turnaround targets.
⚖️ Verdict: 🟢
Bullish. The company is doing exactly what it promised: shedding low-yield assets, buying high-yield assets, controlling leverage, and driving organic growth above 4%.
Key Themes
Accretive Arbitrage: The Ultimate Value Driver
The company's external growth engine is Reversing from defense to aggressive offense. By disposing of $83M in assets at sub-5% cap rates and reinvesting ~$40M (at share) into KKR joint venture acquisitions yielding ~7.5%, HR is capturing a 250+ bps spread. This capital recycling limits the need for dilutive equity issuance while immediately boosting FFO.
High-Yield Redevelopment Engine
Redevelopment remains a top capital priority, targeting 9-12% stabilized yields. In Q2, HR committed $35M to modernize three buildings at the Ascension Saint Thomas West campus in Nashville. This represents a product innovation upgrade, replacing aging infrastructure with a new Heart and Kidney Transplant Center, a Thoracic Surgery Center, and advanced cardiac catheterization labs. Securing 200,000 sq. ft. of leases with a top-10 health system significantly de-risks the investment.
Macro: Favorable Outpatient Supply/Demand
The macro environment remains highly constructive for MOB operators. High construction costs are suppressing new competitive supply, forcing health systems to renew existing spaces. This dynamic is perfectly illustrated by HR's 88.5% retention rate and 4.8% cash leasing spreads for Q2. Demand continues to outstrip supply as services migrate off-campus.
Same-Store NOI Growth Decelerating
While management touts a new era of high growth, the data shows Same-Store Cash NOI growth Decelerating from a peak of 6.9% in 25Q1 to 5.1% in 25Q2. While 5.1% is objectively strong, it contradicts the purely positive narrative that growth will simply continue to compound without friction. Investors must monitor if this normalization drifts back toward the legacy 3% trendline.
The Occupancy Gap Remains
A Persistent theme is the 200-basis-point gap between Same-Store Occupancy (92.7%) and Total Portfolio Occupancy (90.7%). While the stabilized core is performing beautifully, the non-stabilized 'lease-up' portfolio remains a drag on total earnings potential. Closing this gap is the hardest operational hurdle remaining in the 2.0 turnaround plan.
Dilution Risk in Debt Refinancing
Management brilliantly sidestepped a major interest rate headwind by issuing $700M of Exchangeable Senior Notes at 3.00% to repay $600M of maturing bonds. However, exchangeable (convertible) debt introduces future equity dilution risk. While mitigated by a $29M capped call and a concurrent 3.8M share repurchase, the initial exchange price of $23.01 limits the upside torque for current shareholders if the turnaround triggers a massive multiple expansion.
Other KPIs
Stable. The dividend cut executed in 2025 continues to pay dividends in the form of financial flexibility. A 76% payout ratio leaves roughly $26M in quarterly retained cash flow (FAD less dividends), providing organic dry powder to fund redevelopments and tenant improvements without tapping the debt markets.
Stable. Leverage remains exactly where management promised (mid-5x range), down significantly from the 6.1x levels seen a year ago (25Q2). Maintaining this level while transitioning back to net-acquisition mode via the JV strategy proves the sustainability of the balance sheet repair.
Guidance
Accelerating. The midpoint was raised by $0.02 from the April guidance of $1.59-$1.65. While seemingly flat vs FY25's $1.61, it is highly impressive given it absorbs the massive earnings dilution from $1.2B in 2025 asset sales. Core earnings are compounding nicely.
Accelerating. Raised 50 bps at the low end and 25 bps at the high end from the prior range of 3.75% - 4.75%. This indicates supreme confidence in pricing power, annual escalators (currently averaging ~3.0%), and limited move-outs for the remainder of the year.
Key Questions
Scalability of the Sub-5% Disposition Market
You successfully sold $83M of assets at a sub-5% cap rate this quarter. How deep is the buyer pool at these aggressive valuations, and how much more of the portfolio can you realistically recycle at these levels to fund 7.5% JV acquisitions?
Exchangeable Notes Strategy
The issuance of 3.00% exchangeable notes beautifully solved the 2026 debt maturity interest rate headwind. Is this a one-time opportunistic maneuver, or should we expect convertible debt to become a structural part of the capital stack?
Lease-Up Portfolio Timeline
Total portfolio occupancy remains 200 basis points below the same-store pool. What specific milestones should we expect in H2 2026 to prove that the targeted $50M NOI upside from the lease-up portfolio is on track?